BIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015

Similar documents
OVERVIEW OF CANCER PATHOPHYSIOLOGY

OVERVIEW OF CANCER PATHOPHYSIOLOGY

AllinaHealthSystems 1

Development of Carcinoma Pathways

What All of Us Should Know About Cancer and Genetics

TUMOR M ARKERS MARKERS

FACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer?

Colorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.

Cancer statistics (US)

Hereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

Primary Care Approach to Genetic Cancer Syndromes

Lecture 1: Carcinogenesis

Oncology 101. Cancer Basics

Navigators Lead the Way

Biology of Cancer Carcinogenesis Detection Prevention. Kerry Hennessy MSN, RN, AOCN

Introduction to Genetics

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

Information for You and Your Family

PDF // POSITIVE COLON CANCER RESULTS

Caring for a Patient with Colorectal Cancer. Objectives. Poll question. UNC Cancer Network Presented on 10/15/18. For Educational Use Only 1

Lecture 1: Carcinogenesis

Chapter 20 Lecture Outline

Anaplastic A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

colorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018

Cancer Genomics 101. BCCCP 2015 Annual Meeting

Multistep nature of cancer development. Cancer genes

Clinical Colon Cancer Abby Siegel MD COLON CANCER. 1. Epidemiology 2. Risk factors 3. Manifestations 4. Treatment

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Familial and Hereditary Colon Cancer

Overview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology

Cancer 101 Spring Family Cancer Retreat 4/18/15. Amish Shah, M.D. New Mexico Cancer Center

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Familial and Hereditary Colon Cancer

11/29/2017. Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR. Genetics 101. Transcription vs Translation

Curable cancers: Progress in Oncology. Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka.

Neoplasia 2018 lecture 11. Dr H Awad FRCPath

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

Chapter 9, Part 1: Biology of Cancer and Tumor Spread

General Surgery Grand Grounds

Lynch Syndrome. Angie Strang, PGY2

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

oncogenes-and- tumour-suppressor-genes)

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2

After Ovarian Cancer Treatment

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome

Cell Death and Cancer. SNC 2D Ms. Papaiconomou

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Aberrant cell Growth. Younas Masih New Life College of Nursing Karachi. 3/4/2016 Younas Masih ( NLCON)

What is DNA? DNA is a double helix formed by base pairs attached to a sugar-phosphate backbone.

Page 1 of 8 TABLE OF CONTENTS

Connections Between Autoimmune Disease & Cancer

Serrated Polyps and a Classification of Colorectal Cancer

CANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

COLON CANCER PROFILE 2012} Cancer Outcomes Analysis Report. The Institute for. Cancer Care

CANCER GENETICS PROVIDER SURVEY

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Colorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi

Introduction. Why Do MSI/MMR Analysis?

Genetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:

Colonic Polyp. Najmeh Aletaha. MD

Quiz. b. 4 High grade c. 9 Unknown

3/9/2017. Chapter 56. Care of the Patient with Cancer. Cancer Rates in the US. Carcinogenesis

Colonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern

number Done by Corrected by Doctor Maha Shomaf

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE

Colorectal cancer Chapelle, J Clin Oncol, 2010

Outcomes Report: Accountability Measures and Quality Improvements

Tumor Markers & Cytopathology

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer

Acute: Symptoms that start and worsen quickly but do not last over a long period of time.

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

Razvan I. Arsenescu, MD Assistant Professor of Medicine Division of Digestive Diseases EARLY DETECTION OF COLORECTAL CANCER

Neoplasia 18 lecture 6. Dr Heyam Awad MD, FRCPath

EARLY DETECTION OF COLORECTAL CANCER. Epidemiology of CRC

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

University of Cyprus Biomedical Imaging and Applied Optics. ECE 370 Introduction to Biomedical Engineering. Cancer

Colon, or Colorectal, Cancer Information

Bihong Zhao, M.D, Ph.D Department of Pathology

Genetics of Oncology. Ryan Allen Roy MD July 8, 2004 University of Tennessee

Precision Genetic Testing in Cancer Treatment and Prognosis

Lynch Syndrome. A Patient s Guide to Genetic Testing for Lynch Syndrome

Colorectal Cancer in 2006: New Developments

Introduction to Basic Oncology

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

CANCER = Malignant Tumor = Malignant Neoplasm

Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer

Hereditary Gastric Cancer

BIT 120. Copy of Cancer/HIV Lecture

BOWEL CANCER. Causes of bowel cancer

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

CELL CYCLE REGULATION AND CANCER. Cellular Reproduction II

Transcription:

BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the Cell Cycle 1

Differences between malignant & normal cells Schematic of Cell: Normal or Malignant Targeting Pathways downstream of K-Ras Oncogene in Lung Adenocarcinoma Co-treatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib The activating BRAF mutation has been identified in many cancers, including: colon & lung adenocarcinomas, papillary thyroid cancer, malignant melanoma & hairy cell leukemia. Malignant melanoma & HCL are of particular interest because of both the high proportion of cases harboring the mutation and the dramatic responses to BRAF inhibitor therapy reported in the literature. Patients with Hairy Cell Leukemia & malignant melanoma present with the BRAF p.v600e mutation, but may be successfully treated for both cancers with the BRAF inhibitor dabrafenib (Tafinlar). Source: http://www.jnccn.org/content/13/1/9 2

Intracytoplasmic Signal Inhibition: small molecule inhibitors, mtor Inhibitors, PARP inhibitors and Proteasome Inhibitors Extracelluar Receptor Inhibition via Monoclonal Antibody Mechanism of Action Can we use the photo on page 35 of the new text under this section heading It is a photo from IMER So What Causes Cancer? Carcinogenesis 3

Many Cancer Types Caused by Bad Luck of Random Mutations (Source: Science 1-2-15) Cancer is an insidious disease that often strikes individuals who lack any type of known risk factors, and new research shows that many cancer types can be chalked up to "bad luck. Using a statistical model to measure proportion of cancer incidence across 31 tissue types, Johns Hopkins University School of Medicine researchers found that 22 cancers, (2/3 s of the total reviewed), could be largely explained by the "bad luck" or random mutations that arise during DNA replication in normal, noncancerous stem cells. The remaining 9 cancer types were more attributable to environmental, lifestyle, and hereditary factors. Focus on stem cell division the more divisions taking place e.g. stem cell turn-over, the more prone tissue is to develop cancer Causes of Carcinogenesis 1. Apoptosis Gene (programmed cell death). May be inactivated in cancer. 2. DNA Repair Gene (repairs abnormal copies / signals cell if unable to repair) 3. Proto-oncogene (signals cell to begin replicating, enter cell cycle) 4. Tumor suppressor gene (instructs cell to stop division) 5. Double helix DNA ladder base pair: Adenine + Thymine; Cytosine + Guanine 6. Nucleotide arrangement /order creates genes, which sit on 23 chromosomes New Research: Stress & Inflammation Combine to Fuel Cancer Growth Definitions Stress: Experience of significant or negative life event or an event without effective coping. Psychological / physiologic response to body perceives as a threat. Inflammation: Cellular manifestation stress. Acute, i.e. innate immunity activates immune system to ward off infection or Chronic, i.e. lingering inflammation can predispose individuals to illness such as cancer. Stress & inflammation probably mediate cancer development & progressions. 25% of cancers are associated with chronic inflammation of broad origin. Source: http://connect.ons.org/columns/five-minute-in-service/stress-and-inflammation New Research: Stress & Inflammation Combine to Fuel Cancer Growth Many cancer-related deaths caused by treatment resistantmetastases. Stress & inflammation play role in metastatic steps. Body produces pro-inflammatory markers in response to stress. Cytokines (proteins that function as molecular messengers between cells) are such a marker. Cytokines regulate immune responses and inflammation. Two pro-inflammatory cytokines are interleukins and tumor necrosis factor; work by turning on various transcription factors. Inflammation changes tissue homeostasis; this leads to chronic response promoting tumor growth, angiogenesis, invasion & metastasis by activating surrounding stromal cells & recruiting inflammatory cells (e.g. mast cells, neutrophils, leukocytes, natural killer cells). These cells generate reactive O2 & Nitrogen species, activating oncogene & shut off tumor suppressor gene Source: http://connect.ons.org/columns/five-minute-in-service/stress-and-inflammation 4

Psycho-Oncology Interventions for Managing Stress and Inflammation in Cancer Theories of Cancer Development Mind-body techniques * Yoga Mindfulness * Cognitive / Behavioral therapy Meditation * Energy-Based Techniques Reiki * Acupuncture Acupressure * Meridian tapping Natural Products * Vitamins and minerals Botanicals * Fish Oils Probiotics * Exercise Walking * Swimming / Hiking Bicycling * Zumba / Dance Fitness Source: Payne, J.K. (2014). State of the Science: Stress, Inflammation, and Cancer. Oncology Nursing Forum, 41(5), 533-540. Genetic Influences Associated with Cancer Genetic Mutations 5

Cancer Genetics Hereditary Breast & Ovarian Cancer Syndromes Hereditary Nonpolyposis Colorectal Cancer Syndrome (HNPCC) Autosomal dominant syndrome accounts for 3%-5% of all colorectal cancers Familial Adenomatous Polyposis Syndromes (FAP) Risk of developing colorectal cancer is virtually 100% Associated with endometrial, ovarian, gastric, bile duct, small bowel, renal pelvis, and ureter cancers Four mutations in the genes MSH2, MLH1, PMS2, and MSH6 have been associated Age at onset can occur before age 20 Screening with colonoscopy and upper endoscopy at puberty Colectomy when symptomatic or when number of adenomas is not manageable with polypectomy 6

Genetic Mutations Angiogenesis Angiogenesis The Metastatic Process 7

The Metastatic Process The Metastatic Process Overall most common sites of metastases Bone Brain Liver Lungs Lymph nodes 8

Pathologic Diagnosis of Cancer Pathologic Diagnosis of Cancer 9

Grading and Differentiation Grade: Degree to which the tumor cells resemble parent tissue Tumor Grade GX G1 G2 G3 G4 Grade can not be assessed Well-differentiated (Low grade) Moderately-differentiated Poorly-differentiated Undifferentiated (High grade) α-fetoprotein Diagnostic Biomarkers for Staging and Monitoring Human chorionic gonadotropin-β CA 19-9: CA 125: CEA CA 15-3, CA 27-29, HER2/NEU Fibrin / FDP, BTA, High molecular weight CEA & mucin, chromosomes 3, 7, 9, 17 Thyroglobulin PSA Testicular cancer (nonseminatous) Testicular cancer Pancreatic cancer Ovarian cancer Colon cancer Breast cancer Bladder cancer Thyroid cancer Prostate cancer Four Different Types of Staging Clinical Staging determines how much cancer there is based on physical exam, imaging tests, & biopsies of affected areas. Pathologic Staging only determined from individual patients who ve had surgery to remove a tumor or explore extent of the cancer. Pathologic staging combines results of clinical staging (physical exam, imaging test) & surgical results. Post-Therapy or Post-Neoadjuvant Therapy Staging determines how much cancer remains after patient is 1st treated with systemic (chemo or hormone therapy) and/or radiation therapy prior to surgery or where no surgery is done. Assessed by clinical and/or pathologic staging guidelines. Restaging is used to determine the extent of the disease if a cancer comes back after treatment. Restaging helps determine the and the best treatment options for cancer that has returned. 10

Common Elements of Staging Staging is based on commonly understood knowledge about the way cancer develops and spreads. In most cases, the stage is based on four main factors: Location of the primary (original) tumor Tumor size and extent of tumors T = TUMOR N = NODES TMN Staging Local involvement, invasion e.g. extent of primary tumor Lymph node involvement, e.g. presence / absence of regional lymph node metastases Lymph node involvement (whether or not the cancer has spread to the nearby lymph nodes) Presence or absence of distant metastasis (whether or not the cancer has spread to distant areas of the body) M = METASTASIS Distant location(s), e.g. presence or absence of distant metastases TNM System TNM System 11

TMN System Typical TNM Staging TMN Staging for Lung Cancer 12

TMN Staging for Lung Cancer TMN Staging for Lung Cancer Other Classification Systems Questions? Cotswald Classification World Health Organization (WHO) Lung Cancer: SCLC versus NSCLC 13